Houston-based Liongard's Roar technology is helping its customers get all their IT services under one umbrella. Getty Images

Houston-based startup Liongard, an Information Technology automation and management company, was founded on the idea that managing data and technology for companies shouldn't be so difficult.

Before founding Liongard, CEO Joe Alapat and COO Vincent Tran owned and operated Empact IT, an IT company, for more 10 years. In the decade they owned the company, Alapat said they saw the industry completely change as protecting a business' information and data became more challenging.

"[IT is] not all on one place in a data center anymore: it's in the Cloud, it's on the network, it's in app services and in on-premise [offices]," Alapat says. "The security problem is huge and that's exploding because … we lack visibility into basic things when we're managing IT. We just want to be able to manage it and get back to sanity."

After the duo sold the IT company in 2012, Alapat and Tran used the funds from the sale to launch Liongard in 2015 with the focus of automating the management of the plethora of systems that can overwhelm Managed Service Providers, or IT Service Providers.

"Everyone thinks their IT department is high-tech," Alapat says. "Unfortunately, the department that's supposed to be so high-tech is actually pretty manual. And they won't let on that it's challenging, but it really is [and] there's a lot of manual work involved."

So, Alapat and Tran developed Roar: a software product that creates a single dashboard for all data systems including the Cloud and apps, server networks, and on-site systems to make accessing and protecting the data easier. Alapat said Roar is able to inspect multiple systems and bring back rich information without logging into each different system.

Liongard joined entrepreneurial accelerator Station Houston — an association that helps place young businesses in front of investors — in June 2016 and gained access to its network of mentors, advisers, and investors.

In spring 2018, Liongard completed its Seed Stage round of its capital campaign with $1.3 million in investments. With these initial funds, Liongard was able to put Roar on the market in April 2018 and expand its client base — growing from two clients to now close to 200 customers in less than a year.

This year, the company will launch the second leg of its capital campaign with the goal of raising between $3 million to $4 million to help expand the company further.

Alapat said he thinks the company has been received well by Houston investors because Liongard offers a product that other IT management companies don't.

"No one has a unified way to look across the Cloud and network and apps and services and servers," Alapat

says. "There's plenty of different dashboards and solutions that looks at one or two of those things, but there's no single solution that consolidates all of that. That's what makes us different — that we unify all of that under one umbrella."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.